A Comparison between Therapeutic Effect of Granulocyte Colony-stimulating Factor and Methylprednisolone in Treatment of Patients with Acute Traumatic Spinal Cord Injury

Publish Year: 1395
نوع سند: مقاله ژورنالی
زبان: English
View: 551

متن کامل این Paper منتشر نشده است و فقط به صورت چکیده یا چکیده مبسوط در پایگاه موجود می باشد.
توضیح: معمولا کلیه مقالاتی که کمتر از ۵ صفحه باشند در پایگاه سیویلیکا اصل Paper (فول تکست) محسوب نمی شوند و فقط کاربران عضو بدون کسر اعتبار می توانند فایل آنها را دریافت نمایند.

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJN-2-1_001

تاریخ نمایه سازی: 10 تیر 1396

Abstract:

Background & Aim: Spinal cord injury (SCI) is one of the worst kinds of traumatic injuries with remarkable social and economiceffects on communities.Methods & Materials/Patients: In this prospective randomized clinical trial, 122 patients with traumatic spinal cord injury wereadmitted to Poursina hospital within 48 hours of injury to compare granulocyte colony stimulating factor (G-CSF) and high-dosemethylprednisolone as neuroprotective therapy.Results: In this research, 122 patients were studied out of whom 62 patients were included in the granulociote colony-stimulatingfactor (G-CSF) group with a mean age of 40.4, and 60 patients in the methylprednisolone group with an average age of 40.10 years.55 out of 122 patients (45%) were completely paralyzed (Grade AIS:A) and 67 (55%) were with incomplete spinal injury (GradeAIS:B,C,D). The average American spinal injury association (ASIA) sensory scores in the two groups were similarly compared inthe same four time intervals, and p values were 0.7, 0.3, 0.2, and 0.1. They were not statistically significant.Conclusion: According to the results, the G-CSF was shown to be beneficial in average ASIA motor and sensory scores in the twogroups of male patients at six months of onset of G-CSF treatment (p value=0.04), and average ASIA motor scores improvement inthe falls subgroup patients also differed significantly within six months of onset of G-CSF treatment (p value=0.03). A multicentreprospective randomized clinical trial to compare the placebo effect with G-CSF protocol s treatment, and also assessment of thecost benefits of the common medical treatment versus G-CSF are n eeded.

Authors

Shahrokh Yousefzadeh-chabok

MD, Professor of Neurosurgery, Guilan Road Trauma Research Center, Guilan University of Medical Sciences, Rasht, Guilan, Iran

Babak Alijani

MD, Associate Professor of Neurosurgery,Guilan Road Trauma Research Center, Guilan University of Medical Sciences, Rasht, Guilan, Iran

Mohammadreza Emamhadi

MD, Associate Professor of Neurosurgery,Guilan Road Trauma Research Center, Guilan University of Medical Sciences, Rasht, Guilan, Iran

Hamid Behzadnia

MD, Assistant Professor of Neurosurgery, Guilan Road Trauma Research Center, Guilan University of Medical Sciences, Rasht, Guilan, Iran